Laboratory Diagnostics

 

Mass spectrometry is transitioning from a specialized analytical technology into a mainstream clinical diagnostics platform, creating one of the most significant growth opportunities in laboratory medicine.

For much of its history, mass spectrometry (MS) was confined to research institutions, pharmaceutical laboratories, and specialized reference testing facilities. Its unmatched analytical sensitivity and specificity made it…

The world runs on roughly 150 billion diagnostic tests a year—and that number is climbing faster than the revenue behind it. IVD Test Procedure Volumes, 8th Edition quantifies that divergence with precision, tracking global procedure volumes segment by segment and region by region as the diagnostics industry completes its transition out of the pandemic era.…

The in vitro diagnostics (IVD) industry is a cornerstone of modern healthcare, empowering clinicians to detect disease, monitor health conditions, and guide treatment decisions with precision. As healthcare continues to evolve—driven by rising rates of chronic conditions such as diabetes and cardiovascular disease, along with ongoing and emerging infectious threats—the IVD market is…

Kalorama’s 105-page clinical proteomics report sizes the market by technology and region through 2030, covering mass spectrometry, high-plex affinity assays, digital immunoassays, and spatial proteomics, with company profiles of 16 vendors and analysis of deals, approvals, and trends from 2021 to 2026.

Now in its 11th edition, Kalorama Information’s flagship review of clinical laboratory services gives decision-makers a rigorous, independent read on where diagnostic testing revenue sits today and where it is heading. Built on a 2025 base year, with historical data spanning 2020–2024 and forecasts running through 2030, the report is the reference stakeholders use to…

Kalorama’s 30-Country IVD Market Atlas sizes and forecasts the in vitro diagnostics market across 30 key countries and 18 segments, with five-year projections through 2030 and country-level revenue data updated through June 2026.

The Kalorama Molecular Diagnostics Quarterly Datastream is exclusively available to purchasers of our annual reports: Worldwide In Vitro Diagnostic (IVD) Tests, World Market for Molecular Diagnostics, or Molecular Point-of-Care (mPOC). This quarterly update covers markets detailed in these reports.

Now in its thirteenth edition — Worldwide Market for Point-of-Care (POC) Diagnostic Tests analyzes the global POC diagnostics market with updated insights and forecasts through 2030.

Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 13th Edition delivers a comprehensive, forward-looking evaluation of one of the most strategically important segments of the in vitro diagnostics (IVD) industry.…

The global in vitro diagnostics (IVD) market is entering a period of measured but positive growth, shaped less by disruptive platform launches and more by strategic portfolio realignment, digital integration, and selective innovation. Kalorama Information’s 19th Edition of The Worldwide Market for In Vitro Diagnostic (IVD) Tests examines how industry participants are navigating competitive pressures, cost constraints,…

Immunoassays remain a foundational pillar of the in vitro diagnostics (IVD) landscape, underpinning a broad range of clinical testing applications despite the maturity of many platforms. Their continued relevance reflects both their versatility across disease areas and the steady pace of technological refinement that has sustained growth and clinical adoption over time. This Kalorama Information…

The global market for respiratory and non-respiratory IVD panel-based testing is undergoing continued structural evolution. Panel-based tests allow for the simultaneous detection of multiple pathogens and or resistance markers from a single specimen, supporting efficient workflows, faster time to results, and greater diagnostic confidence. Market growth is increasingly driven by broader clinical adoption and expanding…

Molecular point-of-care testing continues to reshape diagnostic workflows by bringing the accuracy of molecular methods closer to the patient. In Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 11th Edition (2025 to 2030), Kalorama Information examines a market that has matured significantly over the past decade while remaining dynamic. Distinctions between true point-of-care and near patient…